PEPTIDE LOGIC LLC

San Diego, CA · Biotech · Private

Prolactin monoclonal antibodies (PRL-mAbs) for female pain syndromes

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · peptidelogic.com

Sector: Biotech
Headquarters: San Diego, CA
Total capital: $10.4M

Federal grants: $10.4M; 17 awards · 2016–2022; Rank in peer group#254 of 326
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: None on recordNo federal contract awards found.
Granted patents: None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

Latest events

Aug 2022Federal grantHealth and Human S · Phase I · Long acting and peripherally restricted kappa-opioid receptor agonists for acute migraine treatment$199K
Aug 2022Federal grantHealth and Human S · Phase I · Peptide-antibody conjugate kappa-opioid receptor (PAC-KOR) agonists for treatment of chronic itch$499K
Jun 2022Federal grantHealth and Human S · Phase I · Prolactin monoclonal antibodies (PRL-mAbs) for the treatment of female-predominant pain syndromes$199K
Sep 2021Federal grantHealth and Human S · Phase I · Long acting and peripherally restricted kappa-opioid receptor agonists for acute migraine treatment$499K
Jul 2021Federal grantHealth and Human S · Phase I · Prolactin monoclonal antibodies (PRL-mAbs) for the treatment of female-predominant pain syndromes$696K
Jun 2021Federal grantHealth and Human S · Phase I · Prolactin monoclonal antibodies (PRL-mAbs) for the treatment of female-predominant pain syndromes$497K
Aug 2020Federal grantHealth and Human S · Phase II · Peripherally-Restricted Long-Acting Somatostatin Receptor 4 (LA-SSTR4) Agonists for Pain$1.4M

Show 10 earlier federal awards

Sep 2019Federal grantHealth and Human S · Phase II · Peripherally-Restricted Long-Acting Somatostatin Receptor 4 (LA-SSTR4) Agonists for Pain$1.6M
Jul 2019Federal grantHealth and Human S · Phase II · Peripherally-restricted and long-acting kappa-opioid receptor (LA-KOR) agonists for pain$1.4M
Mar 2019Federal grantHealth and Human S · Phase I · Peripherally-restricted and long-acting MAS1(LA-MAS1) agonists for pain$348K
Sep 2018Federal grantHealth and Human S · Phase I · Peripherally-restricted Long-acting Somatostatin Receptor Type 4 (LA-SSTR4) Agonists For Pain$261K
Jul 2018Federal grantHealth and Human S · Phase II · Peripherally-restricted and long-acting kappa-opioid receptor (LA-KOR) agonists for pain$1.5M
Dec 2017Federal grantHealth and Human S · Phase I · Peripherally-restricted Long-acting Somatostatin Receptor Type 4 (LA-SSTR4) Agonists For Pain$279K
Sep 2017Federal grantHealth and Human S · Phase I · Bi Functional Peptides to Block Vasodilation and Vascular Leakage in Sepsis$298K
Aug 2017Federal grantHealth and Human S · Phase I · Bi-Functional Peptides to Block Vasodilation and Vascular Leakage in Sepsis$298K
Aug 2016Federal grantHealth and Human S · Phase I · Long-Acting Peripherally-Restricted Peptidic Kappa Opioid Receptor Agonists for Pain$207K
Jul 2016Federal grantHealth and Human S · Phase I · Long-Acting Peripherally-Restricted Peptidic Kappa Opioid Receptor Agonists for Pain$207K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 326 peers

Line = median

Biotech · Molecule

Federal grantsBelow median

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

Avilar TherapeuticsSimilar federal contract value in Biotech · null in contracts
SUPERNUS PHARMACEUTICALS INCSimilar federal contract value in Biotech · null in contracts
Siolta Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
Biomea Fusion, Inc.Similar federal contract value in Biotech · null in contracts
Azitra Inc.Similar federal contract value in Biotech · null in contracts
Molecular Assemblies, Inc.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.